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Abstract
Summary Prospective Observational Scientific Study In-
vestigating Bone Loss Experience in Europe (POSSIBLE
EU®) is an ongoing longitudinal cohort study that utilises
physician- and patient-reported measures to describe the
characteristics and management of postmenopausal women
on bone loss therapies. We report the study design and
baseline characteristics of 3,402 women recruited from
general practice across five European countries.
Purpose The POSSIBLE EU® is a study describing the
characteristics and management of postmenopausal women
receiving bone loss medications.
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Methods Between 2005 and 2008, general practitioners
enrolled postmenopausal women initiating, switching or
continuing treatment with bone loss treatment in France,
Germany, Italy, Spain and the UK. Patients and physicians
completed questionnaires at study entry and at 3-month
intervals, for 1 year.
Results Of 3,402 women enrolled (mean age 68.2 years
[SD] 9.83), 96% were diagnosed with low bone mass; 55%
of these using dual energy X-ray absorptiometry. Most
women (92%) had comorbidities. Mean minimum T score
(hip or spine) at diagnosis was −2.7 (SD 0.89; median −2.7
[interquartile range, −3.2, −2.2]) indicating low bone
mineral density. Almost 40% of the women had prior
fractures in adulthood, mostly non-vertebral, non-hip in
nature, 30% of whom had at least two fractures and more
than half experienced moderate/severe pain or fatigue.
Bisphosphonates were the most common type of bone loss
treatment prescribed in the 12 months preceding the study.
Conclusions POSSIBLE EU® characterises postmenopausal
women with low bone mass, exhibiting a high rate of
prevalent fracture, substantial bone fragility and overall
comorbidity burden. Clinical strategies for managing
osteoporosis in this population varied across the five
participating European countries, reflecting their different
guidelines, regulations and standards of care.
Keywords Cohort studies . Osteoporosis . Postmenopausal
osteoporosis . Prospective studies
Introduction
Postmenopausal osteoporosis is a systemic skeletal disease
resulting in increased bone fragility and fracture risk
subsequent to a decrease in bone mass and the degradation
of bone microarchitecture [1, 2]. Osteoporosis increases the
risk of fractures, adversely affecting quality of life, which
can result in pain, fatigue and a reduction in activities of
daily living [1, 2].
Despite the availability of several treatment options,
osteoporosis compromises the health of a significant
number of postmenopausal women [1, 2]. Treatment
initiation in this population may be inconsistent and is
often delayed until the late stages of disease [3]. In
addition, almost half of patients do not comply or persist
with bone loss medications within the first year of treatment
[4]. Poor adherence to treatments may be associated with
poor outcomes, including an increased risk of fractures [5].
Furthermore, the thresholds for diagnostic assessment and
treatment vary across countries because of differing
national guidelines and regulatory requirements, although
the European Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis recently provided some
guidance for national level guideline development [5].
Understanding how osteoporosis treatments are being
used and how they are perceived by patients in Europe
will help provide further insights into the management of
osteoporosis care.
The Prospective Observational Scientific Study Investi-
gating Bone Loss Experience in Europe (POSSIBLE EU®)
is a longitudinal cohort study conducted in Europe between
2005 and 2008. It is broadly similar to the recently
described POSSIBLE US™ study conducted in US patients
[6]. POSSIBLE EU® is designed to describe the use of
current bone loss treatments by postmenopausal women
who are initiating or switching bone loss therapies, or who
have been on such therapy for some time. Through the
retrospective and prospective collection of clinical and
patient experience data, POSSIBLE EU® will provide
insights about bone loss therapies and how they were used
by postmenopausal women in Europe between 2005 and
2008. It will also report on the relationship between patient
characteristics and patient behaviours (e.g. medication
adherence) and important outcomes (e.g. fractures, health-
related quality of life and treatment satisfaction).
In addition to describing the design of the POSSIBLE
EU® study, this paper describes the characteristics and
management of postmenopausal women in Europe receiving
bone loss medications.
Materials and methods
Study design and primary outcomes
POSSIBLE EU® was initiated in December 2005, with
enrolment completed in March 2008. The study was
conducted by a total of 215 investigators at 196 sites in
five European countries: France, Germany, Italy, Spain and
the UK. The study was non-interventional and designed
to provide insights into routine clinical practice while
minimising the impact of data collection on clinical
management of participating women. A local or central
institutional ethics committee approved the protocol for
each site. All patients provided written informed consent.
Data collected in this study included: a medical history,
including fractures experienced during adulthood and bone
loss treatments; health-related quality of life and perceptions
about medications in general and, for women already
receiving bone loss treatments, patient-reported experience
of treatment side effects, treatment persistence and adherence,
perceptions about osteoporosis medications and satisfaction
with treatment. Patients were being followed for 1 year.
Given the observational nature of this study, the term
‘bone loss’ was used in the protocol and data collection
forms as a generic term to capture data on ’bone loss
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prevention medication’. More specific clinical terms (e.g.
low bone mass, low bone mineral density, osteoporosis and
osteopenia) were reserved for situations in which a clinical
diagnosis was made or a clinical measure was available
(e.g. when a T score was available by which to assign a
diagnosis of osteoporosis or osteopenia as per World Health
Organization criteria).
Treatment status cohorts
The investigators assigned patients to one of three cohorts
based on prescribed bone loss treatment at study entry.
These cohorts were defined as follows:
1. Inception—newly starting treatment with a bone loss
therapy (no previous therapy within 12 months of entry).
2. Switch—received therapy at any given time during the
previous 12 months and changed therapy as of study
entry visit (including changes in dosing frequency,
mode of administration and/or addition of a new bone
loss therapy).
3. Established—had been receiving the same therapy for
at least 12 months before study entry (with or without
changes in dosage).
Enrolment goals overall were preset for these cohorts: at
least 50% of patients were to be in the inception cohort,
with at least 75% distributed across the inception and
switch cohorts.
Role of the steering committee
This study is managed under the auspices of a steering
committee consisting of clinicians and content area experts
(e.g. epidemiology, patient outcomes, health-related quality
of life and pharmacoeconomics).
Physician selection
Physicians and sites were chosen on the basis of: (a) a
willingness or ability to take part in the study and (b) being
representative of their country with respect to a range of
characteristics, including broad geographical region, urban/
rural distribution, gender of physician and size of practice
(partnership size). Lists of general practitioners (GPs) in
each of the five countries were obtained from commercial
agencies and supplemented with a list of GPs participating
in established research panels in France (MG Recherche)
and the UK (Profiad).
Patient recruitment
Patients were invited to participate in the study during
routine clinical visits to their GPs. Women were eligible to
participate if they were ≥18 years old, ambulatory, ≥1 year
postmenopausal (i.e. no vaginal bleeding or spotting
for ≥12 months) from any cause and initiating or receiving
ongoing bone loss therapy. Eligible therapies included the
following: bisphosphonates, selective oestrogen-receptor
modulators, calcitonin, parathyroid hormone, strontium
ranelate and any other therapies with a marketing author-
isation for the treatment of osteoporosis or commonly used
to treat bone loss. Patients receiving therapy with calcium
and/or vitamin D (singly or together) were included only
when these agents were administered in combination with
an eligible therapy. Women taking hormone replacement
therapy alone were not eligible for inclusion. Women were
excluded if they were participating in or had just completed
other research studies, or if they were taking experimental
treatments. Also, women with medical conditions that
could impact their ability to participate in this study (e.g.
receiving treatment for cancer) were excluded.
Patient retention
Approaches to retain patients in the study were designed to
encourage continued patient participation while having
minimal impact on clinical practice and patient behaviour.
A combination of reminder cards and newsletters were used
to encourage patients to return subsequent questionnaires
on time. Investigators also reminded patients of the
importance of continued participation in the study during
routine visits.
Data collection
Investigators at study sites reported data for each patient at
study entry and at 3-month intervals during the follow-up
period, regardless of whether the patient visited the
practice after study enrolment. Data collected at baseline
included basic demographics, a low bone mass diagnosis,
fracture history during adulthood, bone loss treatment
and comorbidities during adulthood and concomitant
medications. Investigators coded all fractures according
to 22 different locations (or ‘Other’ and ‘Unknown’).
Patients completed a patient-reported outcome (PRO)
questionnaire at enrolment, either at the study site or at home.
Subsequent PRO data were collected from patients via
questionnaires mailed to their homes at 3-month intervals.
These PRO questionnaires were designed specifically for each
cohort to reflect differences in prior treatment history. In
general, the baseline PRO data collected included current
bone loss treatments with information on side effects and
adherence, patient satisfaction with and views on medications
(general and bone loss as appropriate), health status, general
pain and fatigue questions, risk factors for low bone mass and
personal situation. Patient-reported fatigue was assessed using
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the following question: “During the past month, how would
you describe the level of fatigue you usually experienced?”
Patient-reported pain was assessed using the following
question: “During the past month, how would you describe
the level of pain usually experienced?” In addition, health-
related quality of life was assessed using the EQ-5D [7–9],
and using a disease-specific health-related quality of life
instrument—the Osteoporosis Assessment Questionnaire
short form [10] (data not shown).
Data storage and quality assurance
Data quality was assessed by ongoing review of the
following: data return rates, data quality checks, quality of
completion, consistency checks on data provided by
physicians and patients, review of cohort allocation and
ongoing review of medication coding. Data checks were
performed to verify data and queries sent to the study sites.
Data reported by patients were not queried.
Statistical analysis
Descriptive statistics are presented. Two analysis sets were
defined: the full analysis set, which enrolled women with
baseline physician-reported data; and the PRO analysis set,
which enrolled women with a PRO completion date within
the time window of −2/+8 weeks of the indicated enrolment
date. Unless otherwise noted, data described in the text are
from the full analysis set. Data on comorbidities were
collected based on a list of 28 prespecified conditions and
could be classified (yes/no) as ‘ever experienced during
adulthood,’ ‘ongoing’ and ‘currently treated’.
Results
Site and patient enrolment
Overall, data were collected from 3,402 women who had
consented to participate in the POSSIBLE EU® study. Of
these, 2925 completed baseline PRO within the specified
time limit, thereby comprising the PRO analysis set. Across
the five countries, France, Germany and UK each contributed
similar numbers of patients and sites, whereas Italy and Spain
each contributed slightly fewer patients (Fig. 1). Among the
countries, Germany, France, Italy and the UK had, for the
most part, a single investigator per site, with a few sites
having more than one investigator. In contrast, in Spain,
multiple investigators were involved per site.
Demographics
Table 1 summarises patient characteristics across the
cohorts. The percentage of patients across each cohort
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Table 1 Baseline characteristics by cohort
All patients Inception
cohort
Established
cohort
Switch
cohort
Variable (n=3,402) (n=1,787) (n=1,041) (n=574)
Age, years
Number 3,402 1,787 1,041 574
Mean (SD) 68.2 (9.83) 67.4 (10.12) 68.9 (9.27) 69.5 (9.71)
Age at menopause, years
Number 3,278 1,737 1,006 535
Mean (SD) 48.5 (5.50) 48.4 (5.40) 48.7 (5.36) 48.2 (6.06)
Race/ethnicity
Number 3,402 1,787 1,041 574
Caucasian/white, n (%) 3,331 (97.9) 1,747 (97.8) 1,014 (97.4) 570 (99.3)
Black, n (%) 6 (0.2) 3 (0.2) 3 (0.3) 0
Asiana, n (%) 9 (0.3) 3 (0.2) 5 (0.5) 1 (0.2)
Other, n (%) 3 (<0.1) 2 (0.1) 1 (<0.1) 0
Missing, n (%) 53 (1.6) 32 (1.8) 18 (1.7) 3 (0.5)
Living arrangements at baseline (%)
Numberb 2,925 1,525 907 493
Alone, n (%) 861 (29.4) 435 (28.5) 272 (30.0) 154 (31.2)
With spouse/family/others, n (%) 1,963 (67.1) 1,049 (68.8) 591 (65.2) 323 (65.5)
Nursing home/residential care, n (%) 12 (0.4) 9 (0.6) 3 (0.3) 0
Hostel, shelter, group or boarding home, n (%) 20 (0.7) 11 (0.7) 7 (0.8) 2 (0.4)
Unknown/missing, n (%) 69 (2.4) 21 (1.4) 34 (3.7) 14 (2.8)
Employment status
Numberb 2,925 1,525 907 493
Working full-time, n (%)c 169 (5.8) 108 (7.1) 39 (4.3) 22 (4.5)
Working part-time, n (%)c 127 (4.3) 67 (4.4) 41 (4.5) 19 (3.9)
Economically inactive, n (%) 2,523 (86.3) 1,307 (85.7) 788 (86.9) 428 (86.8)
Unknown/missing, n (%) 106 (3.6) 43 (2.8) 39 (4.3) 24 (4.9)
Comorbid conditions, nd
Number 3,402 1,787 1,041 574
No, n (%) 280 (8.2) 166 (9.3) 82 (7.9) 32 (5.6)
Yes, n (%) 3,119 (91.7) 1,620 (90.7) 958 (92.0) 541 (94.3)
Unknown/missing, n (%) 3 (<0.1) 1 (<0.1) 1 (<0.1) 1 (0.2)
Number of comorbiditiese, n 10,556 5,379 3,217 1,960
Mean (SD) no. per patient 3.4 (2.01) 3.3 (1.97) 3.4 (2.05) 3.6 (2.08)
No. patients with comorbid conditions, currently or previously experienced, ne 3,402 1,787 1,041 574
Back pain, n (%) 1,677 (49.3) 891 (49.9) 511 (49.1) 275 (47.9)
Hypertension, n (%) 1,566 (46.0) 831 (46.5) 471 (45.2) 264 (46.0)
Osteoarthritis, n (%) 1,240 (36.4) 619 (34.6) 370 (35.5) 251 (43.7)
Hyperlipidaemia, n (%) 1,169 (34.4) 613 (34.3) 362 (34.8) 194 (33.8)
Upper GI (GERD, reflux, dyspepsia), n (%) 754 (22.2) 335 (18.7) 234 (22.5) 185 (32.2)
Depression, n (%) 640 (18.8) 313 (17.5) 194 (18.6) 133 (23.2)
Vision impairment, n (%) 399 (11.7) 205 (11.5) 120 (11.5) 74 (12.9)
Lower GI (IBS, Crohn's disease), n (%) 302 (8.9) 131 (7.3) 101 (9.7) 70 (12.2)
Cancer, n (%) 300 (8.8) 147 (8.2) 94 (9.0) 59 (10.3)
Diabetes, n (%) 296 (8.7) 180 (10.1) 72 (6.9) 44 (7.7)
Asthma, n (%) 249 (7.3) 109 (6.1) 97 (9.3) 43 (7.5)
Thromboembolic diseases, n (%) 231 (6.8) 124 (6.9) 67 (6.4) 40 (7.0)
COPD, n (%) 214 (6.3) 114 (6.4) 71 (6.8) 29 (5.1)
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Table 1 (continued)
All patients Inception
cohort
Established
cohort
Switch
cohort
Angina, n (%) 194 (5.7) 100 (5.6) 59 (5.7) 35 (6.1)
Other inflammatory disorders, n (%) 192 (5.6) 96 (5.4) 55 (5.3) 41 (7.1)
Rheumatoid arthritis, n (%) 171 (5.0) 74 (4.1) 62 (6.0) 35 (6.1)
Vitamin D deficiency, n (%) 158 (4.6) 73 (4.1) 49 (4.7) 36 (6.3)
Renal disease, n (%) 139 (4.1) 64 (3.6) 44 (4.2) 31 (5.4)
Hyperthyroidism, n (%) 135 (4.0) 82 (4.6) 33 (3.2) 20 (3.5)
Heart valve problems, n (%) 107 (3.1) 60 (3.4) 25 (2.4) 22 (3.8)
Congestive heart failure, n (%) 91 (2.7) 46 (2.6) 22 (2.1) 23 (4.0)
Ulcers, n (%) 90 (2.6) 40 (2.2) 31 (3.0) 19 (3.3)
Neuromuscular dysfunction, n (%) 74 (2.2) 40 (2.2) 18 (1.7) 16 (2.8)
Chronic liver disease, n (%) 72 (2.1) 46 (2.6) 22 (2.1) 4 (0.7)
Coagulopathy 43 (1.3) 22 (1.2) 14 (1.3) 7 (1.2)
Seizure disorders, n (%) 31 (0.9) 17 (1.0) 6 (0.6) 8 (1.4)
Hyperparathyroidism, n (%) 16 (0.5) 6 (0.3) 9 (0.9) 1 (0.2)
Paget’s disease, n (%) 6 (0.2) 1 (<0.1) 4 (0.4) 1 (0.2)
Diagnosed with low bone mass, n (%) 3,260 (95.8) 1,695 (94.9) 1,007 (96.7) 558 (97.2)
Patients diagnosed with low bone mass by method, nf 3,260 1,695 1,007 558
DXA, n (%) 1,784 (54.7) 926 (54.6) 565 (56.1) 293 (52.5)
X-ray, n (%) 813 (24.9) 446 (26.3) 224 (22.2) 143 (25.6)
Clinical (including family and fracture history), n (%) 360 (11.0) 157 (9.3) 126 (12.5) 77 (13.8)
Ultrasound, n (%) 138 (4.2) 73 (4.3) 46 (4.6) 19 (3.4)
Other, n (%) 143 (4.4) 84 (5.0) 37 (3.7) 22 (3.9)
Unknown/missing, n (%) 22 (0.7) 9 (0.5) 9 (0.9) 4 (0.7)
Diagnosis based on DXA, ng 1,784 926 565 293
Osteopenic, n (%) 548 (30.7) 311 (33.6) 157 (27.8) 80 (27.3)
Osteoporotic, n (%) 1,216 (68.2) 605 (65.3) 403 (71.3) 208 (71.0)
Unknown/missing, n (%) 20 (1.1) 10 (1.1) 5 (0.9) 5 (1.7)
Minimum T score (lowest value at hip or spine) at diagnosis, n 1,529 844 439 246
Mean (SD) −2.7 (0.89) −2.7 (0.87) −2.8 (0.91) −2.7 (0.88)
Time since diagnosis (years), n 3,257 1,696 1,003 558
Mean (SD) 3.3 (4.10) 1.9 (3.47) 4.8 (3.98) 4.8 (4.54)
Number of patients with fracture before baseline
Number, n 3,402 1,787 1,041 574
With fracture, n (%) 1,317 (38.7) 630 (35.3) 435 (41.8) 252 (43.9)
COPD chronic obstructive pulmonary disease, DXA dual energy X-ray absorptiometry, GI gastrointestinal, GERD gastro-oesophageal reflux
disease
a Includes Chinese, Bangladeshi, Indian and Pakistani
b Based on patient-reported outcome (PRO) analysis set
c Part-time work defined as working for pay <32 h/week; full-time as working for pay ≥32 h/week
d Has the patient (currently or previously) experienced any of the following comorbid conditions during adulthood (≥18 years of age)
e Number of comorbid conditions currently or previously experienced by patients. Patients may have experienced more than one comorbid
condition. Percentages are based on the total number of patients in the full analysis set
f Percentages based on number of patients with a low bone mass diagnosis reported
g Percentages based on number of patients with a method of bone loss diagnosis reported as DXA
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was 53% (inception), 31% (established) and 17% (switch).
Overall, the mean age of these women was 68.2 years (SD
9.81) at enrolment; their median age at onset of menopause
was 50 years (25th and 75th percentiles, 46, 52). Most were
white; and most (86%) were ‘economically inactive’, i.e.
not in paid employment. For the most part, these women
were either living with other people (i.e. spouses, family or
others; 67%); few were in assisted care facilities.
Table 2 Overview of baseline characteristics by country
Parameter France
(n=846)
Germany
(n=708)
Italy
(n=526)
Spain
(n=567)
UK
(n=755)
Age, years
Number 846 708 526 567 755
Mean (SD) 68.4 (9.90) 71.3 (8.93) 66.5 (9.72) 63.8 (9.16) 69.5 (9.77)
Age at menopause, years
Number 828 681 521 554 694
Mean (SD) 49.6 (4.48) 48.6 (5.94) 48.9 (4.58) 47.9 (5.19) 47.1 (6.59)
Most common living arrangements at baseline
Numbera, n 654 626 459 499 687
Alone, n (%) 222 (33.9) 226 (36.1) 99 (21.6) 89 (17.8) 225 (32.8)
With spouse/family/others, n (%) 415 (63.5) 369 (58.9) 348 (75.8) 392 (78.6) 439 (63.9)
Most common employment status
Numbera, n 654 626 459 499 687
Economically inactive, n (%) 569 (87.0) 576 (92.0) 432 (94.1) 374 (74.9) 572 (83.3)
Diagnosed with low bone mass, n (%) 801 (94.7) 685 (96.8) 517 (98.3) 543 (95.8) 714 (94.6)
Most common methods of low bone mass diagnosis
Number of patients, nb 801 685 517 543 714
DXA, n (%) 471 (58.8) 332 (48.5) 263 (50.9) 269 (49.5) 449 (62.9)
X-ray, n (%) 149 (18.6) 194 (28.3) 185 (35.8) 177 (32.6) 108 (15.1)
Clinical (including family and fracture history), n (%) 155 (19.4) 34 (5.0) 26 (5.0) 37 (6.8) 108 (15.1)
Ultrasound 0 55 (8.0) 29 (5.6) 30 (5.5) 24 (3.4)
Other n (%) 20 (2.5) 65 (9.5) 11 (2.1) 25 (4.6) 22 (3.1)
Unknown/missing, n (%) 6 (0.7) 5 (0.7) 3 (0.6) 5 (0.9) 3 (0.4)
Type of low bone mass diagnosis by DXA, nc 471 332 263 269 449
Osteopenic 200 (42.5) 67 (20.2) 83 (31.6) 76 (28.3) 122 (27.1)
Osteoporotic 263 (55.8) 265 (79.8) 177 (67.3) 189 (70.3) 322 (71.7)
Unknown 8 (1.7) 0 3 (1.1) 4 (1.5) 5 (1.1)
Minimum T score (across all hip/spine measurements) at diagnosis, n 437 277 239 193 383
Mean (SD) −2.6 (0.89) −3.0 (0.97) −2.8 (0.79) −2.7 (0.76) −2.8 (0.90)
Number of patients with fracture before baseline
Number, n 846 708 526 567 755
With fracture, n (%) 301 (35.6) 311 (43.9) 148 (28.1) 167 (29.5) 390 (51.7)
Number of previous fractures by location
Numberd 412 501 196 217 584
Hip, n (%) 37 (9.0) 21 (4.2) 21 (10.7) 10 (4.6) 50 (8.6)
Vertebral (spine), n (%) 88 (21.4) 158 (31.5) 55 (28.1) 41 (18.9) 89 (15.2)
Non-vertebral/non-hipe, n (%) 284 (68.9) 321 (64.1) 118 (60.2) 166 (76.5) 445 (76.2)
DXA dual energy X-ray absorptiometry
a Based on patient-reported outcome (PRO) analysis set
b Percentages based on the number of patients with a bone loss diagnosis reported
c Percentages based on the number of patients with a method of bone loss diagnosis reported as DEXA
dNumber of fractures reported. Patients may have experienced more than one location of prior fractures
e Includes all fracture locations other than hip and vertebral (spine)
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Table 2 provides a general summary of patient character-
istics by country, irrespective of cohort. The mean age at
enrolment ranged from 63.8 years in Spain to 71.3 years in
Germany. Spain had the lowest proportion of ‘economically
inactive’ women (75%), and Italy and Germany had the
highest (94% and 92%, respectively). The proportions of
women living alone or with others appeared to vary slightly
between countries, with the highest levels of living with
other people being reported in Italy and Spain (76% and
79%, respectively), compared with 59% in Germany.
Comorbid conditions
Most women (92%) experienced, either currently or
previously, at least one of the prespecified comorbid
conditions, with a mean (SD) number per patient 3.4
(2.01; Table 1) and a median of three conditions (25th and
75th percentiles, 2, 5) per patient. The two most common
comorbidities were back pain (49%) and hypertension
(46%). Although upper gastrointestinal comorbid condi-
tions were reported in 22% of all patients, they were more
commonly reported in the switch cohort (32%) than in the
other two cohorts (19% inception, 23% established;
Table 1). Osteoarthritis was also reported more frequently
in the switch cohort (44%) than in the other two cohorts
(35% inception, 36% established; Table 1).
Diagnosis
Of 3,402 women, 96% had a diagnosis of low bone mass
(Table 1). Among those diagnosed, the most common
methods of diagnosis were dual energy X-ray absorptiometry
(DXA; 55%), followed by traditional X-ray (25%) and
clinical history (11%; Table 1). Use of DXA for diagnosis
permitted further characterisation of low bone mass as either
osteopenic (31%) or osteoporotic (68%; Table 1). Among
patients for whom DXA results were available at diagnosis,
the mean minimum T score across all sites (i.e. femoral neck,
total hip and lumbar spine) was −2.7 (SD 0.89; Table 1;
median −2.7 [interquartile range. −3.2, −2.2]) with little
variation across cohorts. Of the patients for whom no DXA
results were available at diagnosis (43%), 55% were
diagnosed by X-ray. Bone marker and vitamin D tests were
rarely performed in these patients in the 3 months prior to
study entry (in 3% and 3% of patients, respectively).
Table 2 shows country-level differences in both diagnostic
approaches and level of disease progression in the study
populations. The highest rate of diagnosis by DXAwas in the
UK (63%) and the lowest in Germany (49%). The highest use
of X-rays was in Italy (36%) versus 15% in the UK; diagnosis
by ‘other means’was highest in Germany (10%) and lowest in
Italy (2%). Themeanminimum T scores (at diagnosis) ranged
from −3.0 in Germany to −2.6 in France (Table 2), and the
proportion of women with T scores in the osteoporotic range
was highest in Germany (80%) and lowest (56%) in France.
Fractures
Fractures of the fingers, face, skull and toes were excluded.
Overall, 1,317 (39%) women had experienced fractures
during adulthood (Table 2 and Fig. 2); 12% of these women
had at least two fractures. The corresponding percentages
Wrist 403 (30%)
Ankle 153 (11%)
Forearm 121 (9%)
Foot 103 (8%)
Ribs 96 (7%)
Upper arm 92 (7%)
Lower leg (not knee or ankle) 72 (5%)
Pelvis (not hip) 53 (4%)
Shoulder 49 (4%)
Upper leg (not hip) 47 (4%)
Knee 38 (3%)
Other 33 (2%)
Hand 28 (2%)
Collar bone 15 (1%)
Knee cap 14 (1%)
Breast bone 9 (1%)
Tailbone 8 (1%)
Unknown,
n=6, 0.3%
Vertebral,
n=431,23%
Hip,
n=139, 7% Non-hip,non-vertebral
n=1334, 70%
Prevalence of non-vertebral, non-hip
fracture in descending order of
frequency (n=1334)
Note: % is calculated as % NHNV Fractures
Fig. 2 Prior fracture in
adulthood by location (full
analysis set). Percentages
in the pie chart are reported
as percentage of total number
of fractures; percentages in
the table are reported as
percent of non-hip,
non-vertebral fractures.
Overall, 1,910 prior
fractures were reported
in this population
68 Arch Osteoporos (2010) 5:61–72
were slightly higher among women in the established
cohort (42% and 14%, respectively) and those in the switch
cohort (44% and 15%, respectively), compared with values
in the inception cohort (35% and 9%, respectively). Among
the 1,910 fractures reported and characterised by location
(hip, vertebral and non-hip, non-vertebral [NHNV]), 70%
occurred in NHNV locations, with 23% of fractures being
in the spine and 7% in the hip (Fig. 2). Among patients
diagnosed with osteopenia, 32% had a previous fracture
compared with 37% of patients diagnosed with osteoporosis.
Among patients who had no DXA at baseline, 43% had a
previous fracture. Fracture type and prevalence by country is
described in Table 2.
Bone loss medication at baseline
Women in the established and switch cohorts were most
commonly prescribed bisphosphonates in the 12 months
prior to the study (Table 3). Women in the switch cohort
received a broader range of bisphosphonates and other
products such as strontium ranelate.
Patient-reported outcomes
Figure 3 describes the pain and fatigue data for the PRO
analysis set. Fifty-nine percent of women reported experiencing
moderate to severe pain and 54% reported experiencing
moderate to severe fatigue over the previous month.
Reports of pain and fatigue were similar across cohorts.
Discussion
The cohort of postmenopausal women enrolled in POSSI-
BLE EU® describes a cross-section of the women who
received bone loss treatment in five large European
countries within the primary care setting between 2005
and 2008. Broad country-level comparisons of patient age,
living arrangements and work status suggest variation in
how patients are treated or selected for participation in the
study, e.g. participants from Spain are younger and more
likely to be employed, while participants from Germany are
likely to be older and less likely to be employed. This may
reflect differences in the health-care systems of the countries
included in this study (e.g. in Spain, all bone loss medications
are reimbursed whereas in Germany there are certain
restrictions, such as the requirement for a DXA-based
diagnosis, which, in turn, is only reimbursed in patients with
prior fractures). Other factors that may contribute to the
differences observed include country-specific treatment
guidelines [11–15], physician attitudes about osteoporosis
and the study design (e.g. how sites and investigators were
selected).
In POSSIBLE EU®, 84% of the womenwith a diagnosis of
low bone mass were diagnosed through imaging methods.
Slightly more than half (55%) of all women were diagnosed
using DXA. This contrasts with experience in the USA, where
71% of the 4,994 women enrolled in POSSIBLE US™ had a
diagnostic DXA at, or before, study enrolment [6]. This is
also in line with findings from a recent global study, which
showed that the frequency of bone density testing was 51%
in Europe compared with 85% in Canada [16]. Interestingly,
in our study, although the German group had the lowest
percentage of enrolees for whom DXA findings were
available at the time of diagnosis, this group also contained
the highest percentage of women with T scores in the
osteoporosis range. This finding highlights that in certain
parts of Europe, DXA may be used less often for initial
case-finding and more often for documenting the level of
Table 3 Bone loss treatments during the 12 months preceding baseline
Parameter Established cohort
(n=1,041)
Switch cohort
(n=574)
Taken any bone loss treatments within 12 months of baseline? n (%)
Yes 1,034 (99.3) 570 (99.3)
Noa 7 (0.7) 4 (0.7)
Bone loss treatments, nb 1,034 570
Bisphosphonate, n (%) 894 (86) 541 (95)
Alendronate 536 (52) 366 (64)
Risedronate 263 (25) 256 (45)
Ibandronate 67 (6) 147 (26)
Clodronate 23 (2) 9 (2)
Etidronate 21 (2) 41 (7)
Pamidronate 1 (0.1) 3 (0.5)
Zoledronate 0 2 (0.4)
Neridronate 0 1 (0.2)
Unknown bisphosphonates 0 1 (0.2)
Strontium, n (%) 43 (4) 118 (21)
Strontium ranelate 43 (4) 118 (21)
Selective oestrogen-receptor
modulator, n (%)
102 (10) 75 (13)
Raloxifene 102 (10) 75 (13)
Calcitonin, n (%) 4 (0.4) 8 (1)
Calcitonin 4 (0.4) 8 (1)
Others, n (%) 4 (0.4) 5 (0.9)
Hydroxyapatite 3 (0.3) 5 (0.9)
Disodium monoflurophosphate
and calcium
1 (0.1) 0
Parathyroid hormone 0 6 (1)
Teriparatide 0 6 (1)
Patients could receive more than one medication so percentages may
add up to >100%
a Includes patients that have unknown/missing bone loss treatment
b Indicates the number of patients
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bone mass in patients who have more severe, and possibly
more apparent disease progression. The same may be true
regarding the use of laboratory tests for the assessment of
bone markers and vitamin D levels, which were rarely
performed in this population. Another possibility for the
underutilisation of DXA in certain European countries is that
these patients may have been diagnosed using either DXA or
computed tomography, a common means of diagnosis in
local medical practice. As this was not an explicit option on
the case report form, it may be that a high number of patients
were reported as diagnosed using either X-ray (Table 2) or
other means.
It has been suggested that osteoporosis treatment in the
EU is generally triggered by either a prior fragility fracture
or the identification of ‘significant’ risk factors [5]. Our
data were somewhat in line with this suggestion, as 39% of
the study population had at least one prior fracture. These
data are also in agreement with other multinational
European observational studies [17]. Inter-country varia-
tions, however, suggest that different paradigms or attitudes
exist for determining when to initiate therapy. Interestingly,
31% of the women in whom DXA was performed had a
diagnosis of osteopenia and, of these, 32% had a previous
fracture; despite this, however, they were prescribed bone
loss treatment. In most of these countries, access to bone
loss treatment is restricted to those diagnosed with
osteoporosis and/or prior fracture. This finding invites
further investigation to better understand this observation.
Results from the sibling study, POSSIBLE US™, were
recently published [6]. While broadly similar, the design of
the two studies differs in a few key aspects, which include
broad country differences given the geographic regions
represented and differences associated with treatment by
either specialists or GPs or by only GPs. Indeed, in
POSSIBLE US™ the physicians selected for participation
were the top 40% of office-based primary care physicians
(including obstetrics/gynaecology) who prescribed medica-
tion for postmenopausal women with osteoporosis, whereas
in POSSIBLE EU® physicians/sites were chosen only on the
bases of their willingness to participate or if they represented
their country across a broad range of characteristics. The two
studies started nearly a year apart, with POSSIBLE EU®
starting in December 2005 and POSSIBLE US™ in October
2004. Other differences in study design will inform the
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Fig. 3 Percentages of women
reporting pain and fatigue of
various severities, based on the
PRO analysis set. Patients
graded their pain and fatigue
over the past month according to
a five-point scale (none, very
mild, mild, moderate and
severe) in response to the
following questions: “During
the past month, how would you
describe the level of fatigue you
usually experienced?” and
“During the past month, how
would you describe
the level of pain usually
experienced?”
70 Arch Osteoporos (2010) 5:61–72
interpretation of data collected during the follow-up phases of
each study. Compared with the women in POSSIBLE US™,
the women in the EU® study are older and overall less
healthy, with more substantial osteoporosis (mean minimum
T score at diagnosis, −2.7 versus −2.1 [CI, −2.2, −2.1] in
POSSIBLE US™). As expected with observational studies,
patients in both of these studies differ from those who
commonly participate in clinical trials, presenting with greater
degrees of comorbidity and variability in prior treatment
experience.
Women in POSSIBLE EU® reported moderate to severe
pain and fatigue. Further exploration of the comorbidity
data and health-related quality of life gathered in this study
may provide useful insight into this disease state.
POSSIBLE EU® is one of the larger cohorts available
for examining bone loss treatment in postmenopausal
women in European countries. There are other ongoing/
completed observation studies in Europe, but most of the
more recent studies are country specific [18–20]. As this
study is observational, it was designed to minimise the
influence of the study on patient and physician behaviours.
For example, there were no scheduled office visits for this
study and, after consent was obtained, the only communi-
cation with participating patients was through mailed
questionnaires and reminders. However, this study has
certain limitations, mainly unquantifiable factors that may
have affected either the physicians’ selection of patients for
study recruitment or self-selection on the patients’ part to
create a study population that may not fully represent the
general population of interest. In addition, the process of
site selection and measures used to remind participating
patients may have contributed to bias. Furthermore, it is
also likely that the ratio of newly treated, switching and
established patients in the study cohort differs from that found
in actual practice, although such differences should have little,
if any, impact on our ability to address the primary objectives
of this study, which are to examine relationships between
patient characteristics and patient behaviours (e.g. medication
adherence) and important outcomes (e.g. fractures, quality of
life and treatment satisfaction).
In summary, POSSIBLE EU® is a large study aimed at
describing the characteristics of postmenopausal women
who received bone loss treatment in primary care practices
in five European countries between 2005 and 2008. Use of
DXA for diagnosis varied among countries, but was the
main basis for a diagnosis of osteoporosis. The partic-
ipants had substantial prevalence of fractures and pain.
Future analyses will examine quality of life in greater
detail, quantify medication adherence and identify key
correlates (e.g. medication beliefs, treatment satisfaction
and patient-reported side effects), characterise fractures
and compare practice patterns across countries and with
clinical guidelines.
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